Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is
poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19
CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell
hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target
expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical
experiments is cheerful.however, how to select the functional T cells from the malignant T
cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the
majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of
the host as the material of anti-CD7 universal CAR-T cells could be accessible and
affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell
hematologic malignancies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Xinqiao Hospital of Chongqing
Collaborators:
920th Hospital of Joint Logistics Support Force 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Central South University Fujian Medical University Union Hospital Gracell Biotechnologies (Shanghai) Co., Ltd Gracell Biotechnology Shanghai Co., Ltd. Nanfang Hospital of Southern Medical University Second Affiliated Hospital of Xi'an Jiaotong University Tang-Du Hospital The Affiliated Hospital Of Guizhou Medical University The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Kunming Medical College The General Hospital of Western Theater Command The Second Affiliated Hospital of Chongqing Medical University